Informations

There is currently a lack of consensus on whether surgical treatment should be performed for patients with stage IV breast cancer at the initial diagnosis. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled “Surgery of the primary for stage IV disease” garnered global expert attention.

Neoadjuvant therapy is of great significance for the comprehensive treatment of HER2-positive breast cancer. With the updating and improvement of anti-HER2 treatment concepts, more and more HER2-targeted therapeutic drugs are approved and gradually move towards clinical application.

Breast cancer, one of the most prevalent malignant tumors among women, poses a significant threat to their health. Surgery is an essential localized treatment for these patients, and dealing with axillary lymph nodes, breast conservation, and reconstruction are crucial components in transitioning to individualized treatment.